Tebipenem HBr Gets Priority Review for Oral Treatment of Complicated UTI

The FDA has accepted for Priority Review the NDA for tebipenem HBr to treat adults with complicated urinary tract infections, including pyelonephritis.

Related Keywords

Ankit Mahadevia ,Drug Administration ,Priority Review ,New Drug Application ,Prescription Drug User Fee Act ,Qualified Infectious Disease Product ,Fast Track ,